Literature DB >> 25596031

Escherichia coli ST131: The quintessential example of an international multiresistant high-risk clone.

Amy J Mathers1, Gisele Peirano2, Johann D D Pitout3.   

Abstract

Escherichia coli ST131 emerged during the early to mid-2000s is an important human pathogen, has spread extensively throughout the world, and is responsible for the rapid increase in antimicrobial resistance among E. coli. ST131 is known to cause extraintestinal infections, being fluoroquinolone resistant, and is associated with ESBL production most often due to CTX-M-15. Recent molecular epidemiologic studies using whole-genome sequencing and phylogenetic analysis have demonstrated that the H30 ST131 lineage emerged in early 2000s that was followed by the rapid expansion of its sublineages H30-R and H30-Rx. Escherichia coli ST131 clearly has all of the essential characteristics that define a high-risk clone and might be the quintessential example of an international multiresistant high-risk clone. We urgently need rapid cost-effective detection methods for E. coli ST131, as well as well-designed epidemiological and molecular studies to understand the dynamics of transmission, risk factors, and reservoirs for ST131. This will provide insight into the emergence and spread of this multiresistant sequence type that will hopefully lead to information essential for preventing the spread of ST131.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Escherichia coli; ExPEC; High-risk clone; Sequence type 131

Mesh:

Substances:

Year:  2014        PMID: 25596031     DOI: 10.1016/bs.aambs.2014.09.002

Source DB:  PubMed          Journal:  Adv Appl Microbiol        ISSN: 0065-2164            Impact factor:   5.086


  39 in total

1.  Fate of CMY-2-Encoding Plasmids Introduced into the Human Fecal Microbiota by Exogenous Escherichia coli.

Authors:  Valeria Bortolaia; Luca Guardabassi; Mehreen Anjum; Jonas Stenløkke Madsen; Joseph Nesme; Bimal Jana; Maria Wiese; Džiuginta Jasinskytė; Dennis Sandris Nielsen; Søren Johannes Sørensen; Anders Dalsgaard; Arshnee Moodley
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Extended-Spectrum-β-Lactamase- and Plasmid AmpC-Producing Escherichia coli Causing Community-Onset Bloodstream Infection: Association of Bacterial Clones and Virulence Genes with Septic Shock, Source of Infection, and Recurrence.

Authors:  Inga Fröding; Badrul Hasan; Isak Sylvin; Maarten Coorens; Pontus Nauclér; Christian G Giske
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 3.  Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Tam T Van; Emi Minejima; Chiao An Chiu; Susan M Butler-Wu
Journal:  J Clin Microbiol       Date:  2019-06-25       Impact factor: 5.948

4.  Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens.

Authors:  Samuel A Shelburne; Jiwoong Kim; Jose M Munita; Pranoti Sahasrabhojane; Ryan K Shields; Ellen G Press; Xiqi Li; Cesar A Arias; Brandi Cantarel; Ying Jiang; Min S Kim; Samuel L Aitken; David E Greenberg
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

5.  Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli.

Authors:  Aaron E Lucas; Ryota Ito; Mustapha M Mustapha; Christi L McElheny; Roberta T Mettus; Sarah L Bowler; Serena F Kantz; Marissa P Pacey; A William Pasculle; Vaughn S Cooper; Yohei Doi
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

6.  Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.

Authors:  Mariana Castanheira; Timothy B Doyle; Rodrigo E Mendes; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005-2014.

Authors:  P J Stapleton; D J Lundon; R McWade; N Scanlon; M M Hannan; F O'Kelly; M Lynch
Journal:  Ir J Med Sci       Date:  2017-01-04       Impact factor: 1.568

8.  Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Authors:  Darren Abbanat; Todd A Davies; Karen Amsler; Wenping He; Kellen Fae; Sarah Janssen; Jan T Poolman; Germie P J M van den Dobbelsteen
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

9.  Epidemiology and Antimicrobial Resistance Characteristics of the Sequence Type 131-H30 Subclone Among Extraintestinal Escherichia coli Collected From US Children.

Authors:  Arianna Miles-Jay; Scott J Weissman; Amanda L Adler; Veronika Tchesnokova; Evgeni V Sokurenko; Janet G Baseman; Danielle M Zerr
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 9.079

10.  Novel Phagocytosis-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli From Keratitis.

Authors:  Daria Van Tyne; Joseph B Ciolino; Jay Wang; Marlene L Durand; Michael S Gilmore
Journal:  JAMA Ophthalmol       Date:  2016-11-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.